Stimulant Use Disorder: Symptoms, Causes, Diagnosis, and Evidence-Based Treatment

Stimulant use disorder is a clinical condition defined by a pattern of compulsive stimulant use that leads to escalating harms, loss of control, and significant impairment in daily functioning. In the DSM-5-TR (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision), it falls under the category of substance use disorders and applies to the misuse of substances such as cocaine, amphetamines, methamphetamine, and prescription stimulants like those used to treat ADHD (e.g., methylphenidate, mixed amphetamine salts).

The disorder exists on a spectrum of severity — mild, moderate, or severe — determined by how many diagnostic criteria an individual meets. At its core, stimulant use disorder is characterized by a persistent inability to reduce or stop stimulant use despite clear negative consequences to health, relationships, work, and overall well-being.

How common is it? According to estimates from the National Institute on Mental Health (NIMH) and the Substance Abuse and Mental Health Services Administration (SAMHSA), approximately 0.2–0.5% of the adult U.S. population meets criteria for cocaine use disorder in a given year, and an estimated 0.2–0.7% meets criteria for amphetamine-type stimulant use disorder. However, these figures likely underestimate the true prevalence because many individuals do not seek treatment or disclose use. The global burden is substantial: the United Nations Office on Drugs and Crime estimates that tens of millions of people worldwide use amphetamine-type stimulants or cocaine annually.

It is critical to distinguish between prescribed stimulant use that is monitored therapeutically — such as stimulants taken under medical supervision for ADHD — and stimulant misuse. A person using a stimulant exactly as prescribed, at therapeutic doses, under regular clinical follow-up, does not meet criteria for stimulant use disorder simply by virtue of taking the medication. The disorder involves a pattern of compulsive, harmful, and uncontrolled use.

The DSM-5-TR outlines 11 criteria for stimulant use disorder. A person must meet at least two within a 12-month period for a diagnosis to be considered. The severity is graded as mild (2–3 criteria), moderate (4–5 criteria), or severe (6 or more criteria). The criteria include:

• Taking stimulants in larger amounts or over a longer period than intended.
• Persistent desire or unsuccessful efforts to cut down or control use.
• Spending a great deal of time obtaining, using, or recovering from stimulants.
• Craving — an intense urge or desire to use stimulants.
• Failure to fulfill major role obligations at work, school, or home due to use.
• Continued use despite persistent social or interpersonal problems caused or worsened by stimulant effects.
• Giving up or reducing important activities (social, occupational, recreational) because of use.
• Recurrent use in physically hazardous situations.
• Continued use despite knowledge of a physical or psychological problem that is likely caused or exacerbated by the stimulant.
• Tolerance — needing markedly increased amounts to achieve the desired effect, or diminished effect with continued use of the same amount.
• Withdrawal — experiencing characteristic withdrawal symptoms when stopping, or using the stimulant (or a related substance) to relieve or avoid withdrawal symptoms.

Beyond the formal diagnostic criteria, several behavioral and physical warning signs are particularly characteristic of stimulant use disorder:

• Binges: Extended periods of continuous stimulant use lasting hours or even days, often accompanied by little or no sleep or food intake. Binge patterns are especially common with cocaine and methamphetamine.
• Sleep collapse: Following a binge, individuals often experience prolonged sleep episodes (sometimes 24–48 hours) as the body attempts to recover from extreme sleep deprivation.
• Crash dysphoria: The "crash" is a period of intense depression, fatigue, irritability, and anhedonia (inability to feel pleasure) that follows stimulant binge use. This crash can be severe enough to include suicidal ideation.
• Paranoia and psychotic symptoms: High doses or prolonged use of stimulants can induce suspiciousness, paranoid ideation, auditory or visual hallucinations, and frank psychotic episodes — a condition known as stimulant-induced psychosis.
• Cardiovascular warning signs: Rapid heart rate, chest pain, irregular heartbeat, and elevated blood pressure are red flags that indicate dangerous physiological strain from stimulant use.
• Dramatic weight loss, dental deterioration ("meth mouth"), skin picking, and agitation are additional observable signs, particularly in methamphetamine use disorder.

Stimulant use disorder, like other substance use disorders, arises from a complex interplay of biological, psychological, and environmental factors. No single cause explains why one person develops the disorder while another does not.

Biological and Genetic Factors

• Genetics: Research consistently shows that substance use disorders have a heritable component. Twin and family studies suggest that 40–70% of the risk for developing a substance use disorder is attributable to genetic factors. Specific genetic variations affecting dopamine receptor density, dopamine transporter function, and reward-pathway neurobiology have been implicated.
• Neurobiology: Stimulants exert their effects primarily by increasing dopamine activity in the brain's mesolimbic reward pathway. Repeated stimulant exposure produces neuroadaptive changes — the reward system becomes less responsive to natural pleasures (a process called downregulation), which drives compulsive use to achieve even baseline levels of well-being.
• Pre-existing neurological differences: Individuals with variations in executive functioning, impulse control, or reward sensitivity may be more vulnerable.

Psychological Factors

• Co-occurring mental health conditions: Depression, anxiety, PTSD, ADHD, and personality disorders substantially increase vulnerability. Stimulant use can begin as a form of self-medication for low energy, concentration difficulties, or emotional pain.
• Adverse childhood experiences (ACEs): Trauma, neglect, and abuse during childhood are among the most robust predictors of substance use disorders in adulthood.
• Impulsivity and sensation-seeking traits: These personality dimensions are consistently associated with higher rates of stimulant experimentation and escalation to disorder-level use.

Environmental and Social Factors

• Availability and exposure: Living in environments where stimulants are readily accessible increases risk. Geographic regions with high methamphetamine or cocaine prevalence show correspondingly higher rates of stimulant use disorder.
• Peer influence: Social networks that normalize stimulant use are a powerful risk factor, particularly during adolescence and young adulthood.
• Socioeconomic stressors: Poverty, unemployment, homelessness, and lack of access to healthcare and education create conditions that increase vulnerability.
• Route of administration: Smoking or injecting stimulants produces a more rapid and intense high compared to oral or intranasal use, which accelerates the development of compulsive patterns and physiological dependence.

Diagnosis of stimulant use disorder is made by a qualified clinician — typically a psychiatrist, psychologist, addiction medicine specialist, or other licensed mental health professional — based on a thorough clinical evaluation. The process includes several components:

Clinical Interview

The clinician conducts a detailed assessment of substance use history, including the type of stimulant(s) used, amounts, frequency, duration, route of administration, and patterns of use (e.g., binge versus daily use). The interview also explores the individual's subjective experience, including cravings, perceived loss of control, and awareness of consequences.

DSM-5-TR Criteria Application

The clinician systematically evaluates the 11 diagnostic criteria described above to determine whether a diagnosis is warranted and, if so, at what severity level. The specifiers in the DSM-5-TR also allow notation of whether the individual is in early remission (3–12 months without meeting criteria, except craving), sustained remission (12 or more months), or in a controlled environment.

Screening Instruments

Standardized screening tools can help identify individuals who may benefit from further evaluation. The Drug Abuse Screening Test (DAST-10) is a widely recommended screener — a brief, 10-item self-report measure that flags problematic drug use patterns. A positive screen on the DAST-10 should prompt a more comprehensive clinical assessment.

Substance and Psychosis Risk Assessment

Given the significant risk of stimulant-induced psychosis, clinicians conducting follow-up assessment should specifically evaluate for paranoid ideation, hallucinations, disorganized thinking, and agitation. This is particularly important because stimulant-induced psychotic symptoms can closely mimic primary psychotic disorders like schizophrenia, and the differential diagnosis has major implications for treatment.

Medical Evaluation

A physical examination and laboratory workup are important components of the diagnostic process. Urine drug screens confirm recent use. Cardiovascular assessment (including ECG in some cases) addresses the serious cardiac risks associated with stimulant use. Blood work may assess liver and kidney function, nutritional status, and infectious disease screening (particularly for individuals who inject stimulants).

Rule-Out Considerations

Clinicians must carefully distinguish between prescribed stimulant misuse and monitored therapeutic use. A person who takes a prescribed stimulant for ADHD at the dose directed by their physician, without escalation, compulsive use, or harmful consequences, does not meet criteria for stimulant use disorder. However, if that same person begins taking more than prescribed, obtaining extra medication, or experiencing loss of control and negative consequences, the clinical picture shifts and warrants evaluation for the disorder.

Treatment for stimulant use disorder presents unique challenges because, unlike opioid or alcohol use disorders, there are currently no FDA-approved medications specifically for stimulant use disorder. However, several evidence-based psychosocial treatments have demonstrated clear effectiveness, and pharmacological research is actively ongoing.

Psychosocial Treatments (First-Line)

• Contingency Management (CM): This is the most robustly supported behavioral intervention for stimulant use disorder. CM provides tangible incentives (vouchers, prizes, or monetary rewards) for verified abstinence, typically confirmed through urine drug testing. Meta-analyses consistently show that CM produces the largest treatment effect sizes of any psychosocial intervention for stimulant use. Despite its efficacy, CM has been underutilized historically due to implementation challenges, though recent policy changes have expanded access.
• Cognitive Behavioral Therapy (CBT): CBT helps individuals identify and modify thought patterns and behaviors that maintain stimulant use. It teaches coping skills for managing cravings, avoiding triggers, and developing healthier responses to stress. CBT has a strong evidence base and produces durable effects — its benefits often persist after treatment ends.
• The Community Reinforcement Approach (CRA): CRA is a comprehensive behavioral program that restructures the individual's social, vocational, and recreational environment so that a stimulant-free lifestyle becomes more rewarding than continued use. When combined with contingency management (CRA+CM), outcomes are particularly strong.
• Motivational Interviewing (MI) and Motivational Enhancement Therapy (MET): These approaches are especially useful in early engagement, when individuals may be ambivalent about change. MI helps resolve ambivalence and build intrinsic motivation for recovery.
• Matrix Model: This structured 16-week outpatient program integrates elements of CBT, MI, family education, 12-step facilitation, and relapse prevention. It was specifically developed for stimulant use disorder and has shown efficacy particularly with methamphetamine users.

Pharmacological Research

While no medication has yet received FDA approval for stimulant use disorder, several pharmacological agents are under active investigation:

• Bupropion (an antidepressant with dopaminergic and noradrenergic activity) has shown modest benefits in some populations, particularly those with lighter methamphetamine use.
• Naltrexone combined with bupropion is being studied in clinical trials, with some promising early results for methamphetamine use disorder.
• Topiramate, modafinil, and N-acetylcysteine have all been explored, with mixed results.
• Mirtazapine has shown some benefit in reducing methamphetamine use in certain trials.

Clinicians may also prescribe medications to address co-occurring conditions (depression, anxiety, ADHD) which, when properly treated, can improve substance use outcomes.

Levels of Care

Treatment intensity should match the individual's severity level. Options include outpatient counseling, intensive outpatient programs (IOP), residential treatment, and in some cases, medically supervised inpatient care — particularly when there are serious medical complications, psychotic symptoms, or suicidal ideation during the crash phase.

Recovery from stimulant use disorder is achievable, but it is important to understand that the trajectory is often nonlinear. Relapse is common and should be understood as a part of the recovery process, not a failure of it — a principle now widely emphasized in addiction medicine.

What influences prognosis?

• Severity and duration of use: Longer and heavier use patterns are associated with more neurobiological changes and generally longer recovery timelines. Methamphetamine, in particular, can produce lasting cognitive effects, though research shows significant neurological recovery is possible over months to years of sustained abstinence.
• Route of administration: Individuals who smoked or injected stimulants tend to have more severe courses than those who used orally or intranasally.
• Presence of co-occurring disorders: Untreated depression, PTSD, or ADHD can undermine recovery if not addressed concurrently.
• Social support and environment: Strong recovery capital — including stable housing, employment, supportive relationships, and community connection — is one of the most powerful predictors of sustained recovery.
• Treatment engagement: Research consistently shows that longer duration of treatment engagement correlates with better outcomes. This is particularly true for contingency management and CBT-based interventions.

Neurological recovery: Neuroimaging research demonstrates that dopaminergic function, which is significantly disrupted by chronic stimulant use, shows measurable recovery after approximately 12–18 months of sustained abstinence, though some individuals may experience lingering anhedonia and cognitive difficulties for longer. The brain's capacity for neuroplasticity means that meaningful recovery of reward processing, executive function, and emotional regulation is the norm rather than the exception with sustained abstinence.

Long-term outcomes: Population-level data suggest that among individuals who receive treatment, approximately 40–60% achieve significant periods of remission within five years. Continuing care, peer support (such as mutual aid groups), and addressing social determinants of health all contribute to durable recovery.

Stimulant use disorder frequently co-occurs with other psychiatric and medical conditions. Understanding these associations is important for comprehensive care.

• Stimulant-Induced Psychotic Disorder: One of the most serious psychiatric complications. High-dose or prolonged stimulant use can produce paranoid delusions, auditory and visual hallucinations, and agitation that is clinically indistinguishable from schizophrenia in the acute phase. Symptoms typically resolve within days to weeks of cessation, but some individuals experience prolonged or recurrent psychotic symptoms, especially with repeated episodes.
• Major Depressive Disorder: Depression is extremely common both during active stimulant use (particularly during the crash phase) and in early recovery, when the brain's dopamine system is still recovering. Distinguishing between substance-induced depressive symptoms and an independent depressive disorder requires observation over time.
• Attention-Deficit/Hyperactivity Disorder (ADHD): The relationship between ADHD and stimulant use disorder is clinically complex. ADHD is a risk factor for stimulant misuse, and individuals may initially use stimulants to self-medicate attention and motivation difficulties. Proper diagnosis and monitored treatment of ADHD can reduce the risk of substance misuse.
• Post-Traumatic Stress Disorder (PTSD): Trauma and stimulant use frequently co-occur, and integrated treatment approaches that address both conditions simultaneously yield better outcomes than treating either alone.
• Antisocial Personality Disorder and Borderline Personality Disorder: These personality disorders are overrepresented among individuals with stimulant use disorder and can complicate treatment engagement and interpersonal functioning.
• Cardiovascular Disease: Stimulant use causes vasoconstriction, tachycardia, hypertension, and arrhythmias. Chronic use is associated with cardiomyopathy, myocardial infarction, stroke, and aortic dissection — these represent medical emergencies.
• Infectious Diseases: Individuals who inject stimulants are at elevated risk for HIV, hepatitis B, and hepatitis C. Stimulant-driven sexual risk behavior also increases infectious disease transmission independent of injection use.

If you or someone you know is experiencing patterns consistent with stimulant use disorder, seeking professional evaluation is strongly recommended. The following situations indicate that help should be sought promptly:

• Loss of control: Repeated inability to limit the amount or frequency of stimulant use, despite wanting to cut down.
• Escalating use: Needing more of the substance to achieve the same effect, or finding that the same amount no longer works as it once did.
• Neglecting responsibilities: Missing work, school, or family obligations because of stimulant use or recovery from it.
• Physical health deterioration: Significant weight loss, chest pain, rapid heartbeat, dental problems, or persistent insomnia.
• Psychological distress: Severe depression during the crash phase, persistent anxiety, paranoia, or hearing or seeing things that others do not.
• Relationship damage: Conflicts with loved ones, isolation, or loss of important relationships related to stimulant use.

Seek emergency medical attention immediately if any of the following occur:

• Chest pain, difficulty breathing, or signs of a heart attack or stroke
• Psychotic symptoms — paranoia, hallucinations, or severely disorganized behavior
• Suicidal thoughts or self-harm, particularly during the post-binge crash
• Seizures
• Hyperthermia (dangerously elevated body temperature)

A good starting point for evaluation is a primary care physician, a psychiatrist, or an addiction medicine specialist. The SAMHSA National Helpline (1-800-662-4357) provides free, confidential treatment referrals 24 hours a day, 7 days a week. Many communities also have local addiction treatment agencies and crisis centers that can provide immediate guidance.

Remember: stimulant use disorder is a medical condition, not a moral failing. Effective, evidence-based treatments exist, and recovery is both possible and common with appropriate support.